Evidence strength for the context described on this page.
PEPTIDE ATLAS / COGNITION & SLEEP / DSIP
Not FDA-approvedInsufficient
DSIP
ALSO KNOWN ASEmideltide · delta sleep-inducing peptide
A sleep-associated peptide whose name promises more than the human evidence supports.
01CATEGORYCognition & sleep
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEStudied intravenously; marketed subcutaneously or intranasally
04DOSE BASISHuman research + reported community use
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What DSIP is.
A small peptide isolated in sleep-related research and marketed for insomnia, withdrawal and recovery. Its biology and reproducibility remain uncertain.
HOW IT IS THOUGHT TO WORK
Proposed to influence sleep regulation and neuroendocrine stress systems, without a confirmed therapeutic mechanism.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- No established insomnia treatment benefit
- Improved deep sleep
- Treatment of narcolepsy
- Opioid-withdrawal treatment
- A safe nightly dose
Evidence grade: Insufficient. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Human research + reported community useMost commonly reported sleep-use range: 100–300 mcg subcutaneously 30–60 minutes before bedtime for 2–4 weeks. An indexed human-use record reports 25 nmol/kg intravenously in a different experimental context. The bedtime range is not FDA approved or validated as an insomnia guideline.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Commonly reported nightly for 2–4 weeks, followed by about a 2-week break.
- How to interpret it
- The 25 nmol/kg IV research exposure is not equivalent to a subcutaneous bedtime dose. Interaction risk with alcohol, opioids, benzodiazepines and sedatives is unknown; sleep apnea and persistent insomnia need proper evaluation.
ACTUAL HUMAN DOSES REPORTED IN THE RECORD
Research regimens may use different routes, diagnoses, formulations and monitoring. They cannot automatically be converted into a general protocol.
- Experimental human record: 25 nmol/kg intravenously; indication and monitoring differed from modern clinic sleep use.
- Route
- Studied intravenously; marketed subcutaneously or intranasally
- Duration
- Reported sleep cycles: 2–4 weeks with a break; no established course
- Men & women
- No validated sex-specific dose; the same reported 100–300 mcg range is generally used for men and women.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- Use insomnia history, sleep diary and validated clinical evaluation
- Suspected sleep apnea requires testing, not sedating experimentation
SAFETY
Risks, red flags and reasons to avoid it.
- FDA has not identified sufficient safety information
- Immunogenicity and peptide impurities
- Unknown interactions with sedatives or opioids
- Product identity and sterility risks
- Combining with alcohol, opioids or sedatives
- Driving after use
- Self-treatment of narcolepsy or withdrawal
- Pregnancy
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Not FDA-approved; sold by gray-market and some compounded sources.
The name 'sleep-inducing peptide' is descriptive history, not proof that a commercial vial safely treats insomnia.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP